Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma

Data Collected from the Hungarian Ixazomib Named Patient Program

Gergely Varga, Zsolt Nagy, J. Demeter, Szabolcs Kosztolányi, Árpád Szomor, Hussain Alizadeh, Beáta Deák, Tamás Schneider, Márk Plander, Tamás Szendrei, László Váróczy, A. Illés, Árpád Bátai, Mónika Pető, G. Mikala

Research output: Contribution to journalArticle

Abstract

Ixazomib-Revlimid-Dexamethasone is an all-oral treatment protocol for multiple myeloma with a manageable tolerability profile which was available through a named patient program for Hungarian patients from December 2015 to April 2017. We analyzed the clinical characteristics and survival of 77 patients treated at 7 centers within this program. The majority of patients responded, we found complete response in 9, very good partial response in 8, partial response in 32, minor response or stable disease in 13 and progressive disease in 11 patients. Progression free survival was 11.4 months. There was a trend of longer progression free survival in those with 1 vs. >1 prior treatment, with equally good effectivity in standard risk and high risk cytogenetic groups. The adverse events were usually mild, none leading to permanent drug interruptions. There were 5 fatalities: 3 infections and 2 pulmonary embolisms. Our real word data support the use of Ixazomib-Revlimid-Dexamethasone as a highly effective and well tolerated oral treatment protocol for relapsed myeloma.

Original languageEnglish
JournalPathology and Oncology Research
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Multiple Myeloma
Dexamethasone
Safety
Clinical Protocols
Disease-Free Survival
Pulmonary Embolism
Cytogenetics
ixazomib
lenalidomide
Survival
Infection
Pharmaceutical Preparations
Therapeutics

Keywords

  • Ixazomib
  • Multiple myeloma
  • Named patient program
  • Relapsed

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma : Data Collected from the Hungarian Ixazomib Named Patient Program. / Varga, Gergely; Nagy, Zsolt; Demeter, J.; Kosztolányi, Szabolcs; Szomor, Árpád; Alizadeh, Hussain; Deák, Beáta; Schneider, Tamás; Plander, Márk; Szendrei, Tamás; Váróczy, László; Illés, A.; Bátai, Árpád; Pető, Mónika; Mikala, G.

In: Pathology and Oncology Research, 01.01.2019.

Research output: Contribution to journalArticle

Varga, Gergely ; Nagy, Zsolt ; Demeter, J. ; Kosztolányi, Szabolcs ; Szomor, Árpád ; Alizadeh, Hussain ; Deák, Beáta ; Schneider, Tamás ; Plander, Márk ; Szendrei, Tamás ; Váróczy, László ; Illés, A. ; Bátai, Árpád ; Pető, Mónika ; Mikala, G. / Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma : Data Collected from the Hungarian Ixazomib Named Patient Program. In: Pathology and Oncology Research. 2019.
@article{1c385c4525b1429c887ecc09915e010d,
title = "Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program",
abstract = "Ixazomib-Revlimid-Dexamethasone is an all-oral treatment protocol for multiple myeloma with a manageable tolerability profile which was available through a named patient program for Hungarian patients from December 2015 to April 2017. We analyzed the clinical characteristics and survival of 77 patients treated at 7 centers within this program. The majority of patients responded, we found complete response in 9, very good partial response in 8, partial response in 32, minor response or stable disease in 13 and progressive disease in 11 patients. Progression free survival was 11.4 months. There was a trend of longer progression free survival in those with 1 vs. >1 prior treatment, with equally good effectivity in standard risk and high risk cytogenetic groups. The adverse events were usually mild, none leading to permanent drug interruptions. There were 5 fatalities: 3 infections and 2 pulmonary embolisms. Our real word data support the use of Ixazomib-Revlimid-Dexamethasone as a highly effective and well tolerated oral treatment protocol for relapsed myeloma.",
keywords = "Ixazomib, Multiple myeloma, Named patient program, Relapsed",
author = "Gergely Varga and Zsolt Nagy and J. Demeter and Szabolcs Kosztol{\'a}nyi and {\'A}rp{\'a}d Szomor and Hussain Alizadeh and Be{\'a}ta De{\'a}k and Tam{\'a}s Schneider and M{\'a}rk Plander and Tam{\'a}s Szendrei and L{\'a}szl{\'o} V{\'a}r{\'o}czy and A. Ill{\'e}s and {\'A}rp{\'a}d B{\'a}tai and M{\'o}nika Pető and G. Mikala",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12253-019-00607-2",
language = "English",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma

T2 - Data Collected from the Hungarian Ixazomib Named Patient Program

AU - Varga, Gergely

AU - Nagy, Zsolt

AU - Demeter, J.

AU - Kosztolányi, Szabolcs

AU - Szomor, Árpád

AU - Alizadeh, Hussain

AU - Deák, Beáta

AU - Schneider, Tamás

AU - Plander, Márk

AU - Szendrei, Tamás

AU - Váróczy, László

AU - Illés, A.

AU - Bátai, Árpád

AU - Pető, Mónika

AU - Mikala, G.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Ixazomib-Revlimid-Dexamethasone is an all-oral treatment protocol for multiple myeloma with a manageable tolerability profile which was available through a named patient program for Hungarian patients from December 2015 to April 2017. We analyzed the clinical characteristics and survival of 77 patients treated at 7 centers within this program. The majority of patients responded, we found complete response in 9, very good partial response in 8, partial response in 32, minor response or stable disease in 13 and progressive disease in 11 patients. Progression free survival was 11.4 months. There was a trend of longer progression free survival in those with 1 vs. >1 prior treatment, with equally good effectivity in standard risk and high risk cytogenetic groups. The adverse events were usually mild, none leading to permanent drug interruptions. There were 5 fatalities: 3 infections and 2 pulmonary embolisms. Our real word data support the use of Ixazomib-Revlimid-Dexamethasone as a highly effective and well tolerated oral treatment protocol for relapsed myeloma.

AB - Ixazomib-Revlimid-Dexamethasone is an all-oral treatment protocol for multiple myeloma with a manageable tolerability profile which was available through a named patient program for Hungarian patients from December 2015 to April 2017. We analyzed the clinical characteristics and survival of 77 patients treated at 7 centers within this program. The majority of patients responded, we found complete response in 9, very good partial response in 8, partial response in 32, minor response or stable disease in 13 and progressive disease in 11 patients. Progression free survival was 11.4 months. There was a trend of longer progression free survival in those with 1 vs. >1 prior treatment, with equally good effectivity in standard risk and high risk cytogenetic groups. The adverse events were usually mild, none leading to permanent drug interruptions. There were 5 fatalities: 3 infections and 2 pulmonary embolisms. Our real word data support the use of Ixazomib-Revlimid-Dexamethasone as a highly effective and well tolerated oral treatment protocol for relapsed myeloma.

KW - Ixazomib

KW - Multiple myeloma

KW - Named patient program

KW - Relapsed

UR - http://www.scopus.com/inward/record.url?scp=85061044371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061044371&partnerID=8YFLogxK

U2 - 10.1007/s12253-019-00607-2

DO - 10.1007/s12253-019-00607-2

M3 - Article

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

ER -